| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | NEUTRAL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.62▼ | 3.61▼ | 3.60▼ | 3.37▲ | 3.27▲ |
| MA10 | 3.59▼ | 3.63▼ | 3.65▼ | 3.23▲ | 4.28▼ |
| MA20 | 3.66▼ | 3.52▲ | 3.42▲ | 3.22▲ | 6.06▼ |
| MA50 | 3.37▲ | 3.29▲ | 3.27▲ | 4.56▼ | 20.58▼ |
| MA100 | 3.34▲ | 3.59▼ | 3.81▼ | 6.27▼ | 28.47▼ |
| MA200 | 4.13▼ | 5.19▼ | 5.55▼ | 14.83▼ | 35.64▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.024▼ | -0.009▼ | 0.004▲ | 0.162▲ | 0.621▲ |
| RSI | 51.987▲ | 54.482▲ | 55.023▲ | 48.232▼ | 27.483▼ |
| STOCH | 76.049 | 34.819 | 33.450 | 51.400 | 6.834▼ |
| WILL %R | -58.621 | -72.727 | -49.612 | -28.571 | -83.755▼ |
| CCI | -22.066 | -66.098 | -38.337 | 119.510▲ | -64.988 |
|
Tuesday, November 10, 2026 03:49 PM
SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a ...
|
|
Tuesday, November 10, 2026 09:09 AM
First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/11/26 | 3.69 | 3.74 | 3.43 | 3.56 | 58,707 |
| 10/11/26 | 3.63 | 3.69 | 3.40 | 3.46 | 81,308 |
| 09/11/26 | 3.62 | 3.92 | 3.6068 | 3.80 | 65,950 |
| 06/11/26 | 2.69 | 3.49 | 2.69 | 3.34 | 97,169 |
| 05/11/26 | 2.95 | 2.995 | 2.66 | 2.69 | 16,710 |
| 04/11/26 | 3.01 | 3.035 | 2.93 | 2.95 | 5,450 |
| 03/11/26 | 3.03 | 3.12 | 2.985 | 2.995 | 12,173 |
| 02/11/26 | 3.10 | 3.1113 | 3.00 | 3.07 | 11,625 |
| 30/10/26 | 3.30 | 3.30 | 3.05 | 3.06 | 10,591 |
| 29/10/26 | 3.04 | 3.55 | 3.04 | 3.33 | 14,038 |
|
|
||||
|
|
||||
|
|